By Sabela Ojea 22nd Century Group is selling its GVB Biopharma hemp/cannabis operations to Specialty Acquisition Corporation. The biotechnology company on.
By Dean Seal 22nd Century Group's shares fell to a 12-year low on Tuesday after an analyst removed the price target on the company's stock. The stock dropped.
Heritage Wealth Advisors boosted its position in shares of 22nd Century Group, Inc. (NASDAQ:XXII – Free Report) by 102.0% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 256,195 shares of the biotechnology company’s stock after acquiring an additional 129,372 shares during the quarter. Heritage Wealth Advisors’ holdings in 22nd Century Group were worth […]
22nd Century Group (NASDAQ:XXII – Get Free Report) is scheduled to be releasing its earnings data on Monday, November 6th. 22nd Century Group (NASDAQ:XXII – Get Free Report) last released its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) […]
22nd Century Group, Inc. (NASDAQ:XXII – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 3,730,000 shares, an increase of 45.1% from the September 30th total of 2,570,000 shares. Based on an average daily volume of 744,000 shares, the short-interest […]